A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin

INTRODUCTION: Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D). Currently, no head-to-head trial investigating once-weekly semaglutide as an add-on to basal insulin vs other GLP-1 re...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkowski, Michal, Wilkinson, Lars, Webb, Neil, Weids, Alan, Glah, Divina, Vrazic, Hrvoje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984931/
https://www.ncbi.nlm.nih.gov/pubmed/29713961
http://dx.doi.org/10.1007/s13300-018-0428-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984931/
https://www.ncbi.nlm.nih.gov/pubmed/29713961
http://dx.doi.org/10.1007/s13300-018-0428-y

Ejemplares similares